Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European UnionGlobeNewsWire • 04/15/25
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.Investors Business Daily • 04/10/25
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price TagSeeking Alpha • 04/09/25
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 04/02/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall SquareGlobeNewsWire • 03/24/25
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Zacks Investment Research • 03/14/25
BIIB Starts Felzartamab Phase III Study in AMR in Kidney TransplantZacks Investment Research • 03/12/25
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant PatientsGlobeNewsWire • 03/11/25
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)Seeking Alpha • 03/10/25
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)Seeking Alpha • 03/03/25
Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'Investors Business Daily • 03/03/25
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsyMarket Watch • 02/18/25
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsBusiness Wire • 02/18/25